ubiquitin
protein
recogn
degrad
proteasom
meantim
protein
deubiquitin
variou
deubiquitin
enzym
dub
regul
protein
stabil
within
cell
counterbal
intracellular
homeostasi
mediat
ubiquitin
numer
report
demonstr
aberr
process
ubiquitinproteasom
pathway
upp
regul
ubiquitin
deubiquitin
system
result
failur
balanc
protein
stabil
degrad
failur
lead
tumorigenesi
variou
organ
tissu
mammal
identifi
cation
molecular
properti
variou
dub
critic
understand
cancer
develop
tumorigenesi
therefor
knowledg
dub
associ
cancer
diseas
indispens
develop
effect
inhibitor
dub
chapter
describ
variou
featur
function
cancerrel
dub
addit
summar
sever
inhibitor
specifi
calli
target
certain
dub
cancer
suggest
dub
may
one
ideal
attract
therapeut
target
ubiquitinspecifi
c
proteas
revers
process
ubiquitin
deubiquitin
accomplish
deubiquitin
enzym
dub
act
counterbalanc
regul
fate
protein
requir
catalyt
activ
dub
cellular
process
shown
numer
studi
term
cellular
homeostasi
control
express
level
protein
essenti
abnorm
express
certain
protein
directli
link
cancer
diseas
caus
breakdown
coordin
cellular
system
number
unregul
protein
mediat
ubiquitin
deubiquitin
therefor
necessari
understand
investig
detail
cellular
molecular
mechan
underlin
deubiquitin
activ
addit
target
dub
anticanc
therapi
becom
import
fi
eld
cancer
therapeut
knowledg
dub
associ
cancer
diseas
use
dub
inhibitor
clinic
preclin
studi
present
chapter
proteas
essenti
enzym
catalyz
proteinpeptid
bond
speci
variou
cellular
function
food
digest
ovul
fertil
infl
ammatori
respons
mani
studi
analyz
reveal
role
proteas
research
result
appli
medic
treatment
cancer
divers
diseas
recent
studi
suggest
human
genom
encod
total
proteas
human
proteas
divid
fi
class
accord
catalyt
characterist
serin
proteas
threonin
proteas
cystein
proteas
aspart
proteas
metalloproteas
glutam
proteas
limit
fungal
speci
proteas
serin
proteas
threonin
proteas
cystein
proteas
aspart
proteas
metalloproteas
accord
genom
bioinformat
research
proteasom
fig
cystein
proteas
famili
chapter
focu
cystein
proteas
understand
biolog
function
dub
dub
subfamili
cystein
proteas
revers
abil
ligas
detach
ubiquitin
molecul
ubiquitin
substrat
via
enzymat
activ
fig
dubmedi
process
opposit
ubiquitin
call
deubiquitin
like
ubiquitin
deubiquitin
give
signal
function
protein
modul
activ
therefor
dub
involv
numer
cellular
function
includ
cell
cycl
regul
signal
transduct
membran
traffi
cking
dna
damag
respons
immun
respons
apoptosi
program
cell
death
major
known
signal
ubiquitin
guid
ubiquitin
protein
head
proteasom
protein
degrad
ubiquitinproteasom
pathway
upp
dubmedi
deubiquitin
prevent
proteasom
degrad
substrat
thu
orchestr
revers
posttransl
regul
ubiquitin
deubiquitin
affect
cellular
homeostasi
cell
viabil
base
protein
level
also
protein
function
critic
system
maintain
express
level
function
cellular
protein
healthi
cell
tissu
organ
individu
inde
discuss
later
chapter
breakdown
coordin
regul
function
protein
caus
alter
activ
abnorm
express
level
dub
induc
sever
diseas
includ
cancer
date
almost
human
gene
encod
dub
enzym
identifi
ed
group
follow
fi
class
accord
properti
ubiquitinspecifi
c
proteas
usp
ubiquitin
carboxytermin
hydrolas
uch
ovariantumor
proteas
otu
machadojoseph
diseas
mjd
metalloenzym
jamm
classifi
cation
expand
six
categori
order
includ
recent
identifi
ed
monocyt
chemotact
proteininduc
protein
mcpip
dub
identifi
ed
far
list
tabl
except
jamm
zinc
metalloproteas
dub
conserv
domain
includ
cy
aspasn
domain
associ
catalyt
activ
structur
analysi
perform
divers
dub
reliabl
way
gain
inform
target
protein
activ
function
interact
motif
gener
sever
structur
emerg
divers
studi
molecular
key
featur
dub
ubiquitin
moieti
establish
dub
subfamili
share
similar
sequenc
structur
coordin
ubiquitin
deubiquitin
target
protein
mediat
specifi
c
enzym
ubiquitin
success
action
sever
enzym
requir
fi
rst
step
ubiquitin
ub
consist
amino
acid
activ
ubiquitinactiv
enzym
atpdepend
manner
follow
interact
ubiquitinconjug
enzym
lastli
ubiquitin
transfer
ubiquitin
ligas
case
enzym
need
effi
cient
ubiquitin
addit
monoubiquitin
addit
ubiquitin
conjug
attach
ubiquitin
form
polyubiquitin
chain
revers
process
deubiquitin
enzym
dub
detach
ubiquitin
molecul
ubiquitin
substrat
via
enzymat
activ
process
ubiquitin
chain
proteasometarget
protein
remov
therebi
promot
protein
degrad
recycl
free
ubiquitin
deconjug
ubiquitin
proteasom
process
mediat
certain
dub
includ
process
dub
gener
free
ubiquitin
molecul
prevent
proteasom
degrad
target
protein
stabil
target
protein
gener
usp
famili
member
six
homologueconserv
usp
domain
consist
three
domain
organ
palm
thumb
fi
nger
among
fi
nger
domain
interact
ubiquitin
addit
number
divers
motif
exist
usp
specifi
c
domain
structur
give
uniqu
function
usp
zincfi
nger
usp
domain
domain
present
usp
dusp
locat
moreov
function
domain
present
differ
usp
known
uch
small
size
target
small
peptid
structur
includ
confi
ned
loop
otu
famili
subdivid
three
class
depend
characteristicsotubain
otu
protein
cezann
trabid
otud
josephin
famili
dub
also
consist
four
differ
subfamili
includ
unlik
dub
jamm
zinc
metalloproteas
activ
contain
amshlp
structur
two
conserv
motif
relat
capac
cleav
polyubiquitin
chain
vertebr
balanc
maintain
cell
birth
cell
death
intracellular
signal
variou
stimuli
cell
disproportion
abnorm
protein
express
oncogen
transcript
sever
stimuli
transform
cancer
cell
exampl
treatment
normal
cell
virus
carcinogen
compound
uv
ir
transform
cell
character
lead
function
also
known
fi
rst
found
prostat
cancer
exhibit
oncogen
behavior
deplet
induc
cancer
cell
apoptosi
mainli
regul
stabil
fatti
acid
synthas
fa
frequent
overexpress
malign
tumor
deubiquitin
activ
fa
regul
may
lead
tumorigenesi
addit
associ
mdmx
mdmx
known
oncogen
protein
neg
regul
deplet
enhanc
mdmx
protein
degrad
overexpress
increas
cmyc
level
abl
inactiv
prostat
cancer
cell
fi
nding
one
might
expect
would
strongli
associ
tumorigenesi
regul
mdmx
collabor
cmyc
recent
studi
ad
function
express
cell
death
target
rip
tumor
necrosi
factor
receptorassoci
factor
degrad
tumor
necrosi
factor
tnf
respons
consequ
promot
activ
although
associ
tnf
respons
activ
shown
differ
role
wherein
regul
stabil
upon
tnf
respons
interestingli
deubiquitin
also
lead
regul
cell
migrat
genomewid
gainoffunct
studi
reveal
akt
act
kinas
phosphoryl
phosphoryl
move
cytoplasm
nucleu
molecular
mechan
studi
shown
strongli
associ
transform
growth
type
receptor
deubiquitin
stabil
plasma
membran
addit
deplet
inhibit
breast
cancer
cell
migrat
induc
akt
c
ligas
bind
overexpress
stabil
reduc
stabil
vivo
molecular
mechan
studi
deplet
mef
cell
show
resist
tumorigen
transform
also
known
isol
oncogen
ewe
sarcoma
studi
reveal
gene
encod
deubiquitin
enzym
regul
mammalian
cell
growth
moreov
domain
studi
show
homolog
mitosisregul
gene
aneurysm
bone
cyst
abc
gener
malign
bone
tumor
transcript
deregul
abc
intracellular
function
identifi
ed
regul
gtpase
interact
nterminu
tbc
domain
deplet
decreas
activ
known
herpesvirusassoci
ubiquitinspecifi
c
proteas
hausp
studi
deubiquitin
enzym
usp
famili
herp
simplex
viru
hsv
protein
initi
identifi
ed
protein
interact
two
protein
facilit
viral
replic
addit
herp
viru
regulatori
protein
also
bound
stabil
interact
lead
regul
pml
nuclear
bodi
interact
epsteinbarr
viru
ebv
protein
regul
replic
ebv
infect
close
associ
nasopharyng
carcinoma
npc
protein
disrupt
studi
mechan
cellular
function
show
requir
bind
disrupt
tumor
suppressor
phosphatas
tensin
homologu
pten
studi
cancer
progress
recent
studi
show
pten
interact
lead
regul
pten
local
pten
ubiquitin
ligas
transloc
accumul
nucleu
howev
pten
deubiquitin
releas
cytoplasm
signal
network
tumor
suppressor
identifi
ed
bind
substrat
nuclear
extract
human
lung
carcinoma
cell
known
null
cell
express
prevent
ubiquitin
c
ligas
increas
protein
stabil
overexpress
induc
cancer
cell
apoptosi
phenotyp
depend
exist
cell
make
complex
regul
balanc
express
normal
stress
cell
state
elong
howev
deplet
also
induc
upregul
protein
express
hausp
stabil
regul
phosphoryl
dephosphoryl
via
ataxiatelangiectasiamut
atm
depend
pathway
dephosphoryl
undergo
proteasom
degrad
exampl
hausp
phosphoryl
serinethreonin
kinas
lead
stabil
normal
state
stabil
enhanc
decreas
protein
express
dnadamag
state
howev
dephosphoryl
phosphatas
degrad
decreas
protein
accumul
protein
addit
approxim
phosphoryl
exist
human
cell
thu
express
reduc
adenocarcinoma
recent
one
studi
identifi
ed
novel
gene
associ
oncogenesi
breast
call
frequent
overexpress
breast
cancer
studi
show
increas
level
decreas
express
led
accumul
ubiquitin
known
xlink
deubiquitin
enzym
homologu
drosophila
fat
facet
gene
oncogen
function
found
human
lymphoma
substrat
abundantli
express
mantl
cell
lymphoma
mcl
chronic
myeloid
leukemia
cml
multipl
myeloma
mm
overexpress
stabil
protein
human
lymphoma
deplet
increas
ubiquitin
lead
mm
cell
apoptosi
featur
cancer
confi
rmed
studi
pancreat
ductal
adenocarcinoma
pda
tumor
exhibit
inact
protein
delet
increas
pancreat
tumorigenesi
mice
sequenc
similar
unp
protooncogen
signalosom
csn
conserv
protein
complex
involv
transform
eukaryot
cell
associ
upp
bound
csn
complex
recent
studi
show
cullinr
ubiquitin
ligas
crl
csnbind
partner
associ
degrad
crl
involv
protein
process
deubiquitin
howev
deubiquitin
activ
csnbind
protein
microtubul
endbind
protein
indic
enzym
activ
may
work
differ
select
csnmediat
protein
regul
previous
cancer
cell
marker
fulli
defi
ned
sever
studi
suggest
polycomb
gene
could
marker
identifi
cation
cancer
stem
cell
initi
studi
show
overexpress
malign
tumor
link
polycomb
group
furthermor
act
enzymat
compon
saga
transcript
cofactor
complex
activ
myc
oncogen
thu
consid
posit
marker
cancer
stem
cell
sever
studi
shown
level
colorect
cancer
tissu
highli
express
compar
noncancer
mucosa
tissu
colorect
cancer
growth
significantli
decreas
deplet
addit
recent
studi
demonstr
also
increas
sever
cancer
tissu
breast
cancer
oral
squamou
cell
carcinoma
function
found
durat
mitot
spindl
checkpoint
anaphasepromot
complex
apc
ubiquitin
ligas
activ
promot
progress
anaphas
two
protein
interact
regul
sister
chromatin
separ
sever
studi
indic
overexpress
dysfunct
apc
lead
genom
instabl
variou
cancer
affect
spindl
checkpoint
exhibit
deubiquitin
activ
regul
studi
support
result
nontransform
murin
embryon
fi
broblast
show
aneuploidi
overexpress
addit
level
increas
tcell
leukemia
howev
recent
studi
show
express
decreas
lung
cancer
sever
studi
also
shown
involv
oncogen
function
dub
variou
tumor
instanc
contribut
slitmedi
breast
cancer
cell
migrat
tumor
biopsi
result
indic
overexpress
lung
colon
esophagu
cervix
overexpress
ovarian
cancer
tumorsuppress
function
dub
mainli
deriv
associ
sinc
transcript
factor
fi
nal
gatekeep
dna
damag
repair
cell
death
case
untouch
dna
damag
stabil
activ
essenti
requir
tumor
suppress
therefor
failur
defend
link
cell
surviv
signal
partial
cancer
develop
sever
dub
identifi
ed
regul
stabil
dub
includ
ub
aldehydebind
protein
otubain
normal
condit
unstress
condit
locat
cytosol
regul
ligas
proteasom
degrad
nuclear
export
howev
stress
condit
stabil
transloc
nucleu
involv
stress
respons
upon
atmdepend
phosphoryl
threonin
serin
residu
stabil
transloc
nucleu
activ
deubiquitin
activ
induc
tumor
cell
suppress
express
fbp
transcript
factor
factor
activ
stress
condit
physiolog
signal
also
mediat
extern
stress
signal
turn
protect
upregul
directli
deubiquitin
also
found
deubiquitin
activ
earli
phase
respons
stress
signal
preferenti
make
complex
deubiquitin
lead
rapid
activ
cell
cycl
arrest
transcript
somewhat
differ
capac
dub
toward
unlik
catalyt
activ
dub
deubiquitin
activ
rescu
weak
instead
abil
block
ubiquitinconjug
activ
residu
turn
essenti
inhibit
thu
stabil
activ
result
downregul
function
induc
apoptosi
inhibit
cell
prolifer
anoth
import
pathway
relat
dubassoci
tumor
suppress
signal
transcript
factor
induc
sever
downstream
gene
cell
surviv
infl
ammat
howev
sever
oncogen
mutat
lead
abnorm
activ
case
mani
solid
tumor
well
lymphoid
malign
mani
case
affect
factor
regul
ubiquitin
thu
opposit
process
deubiquitin
signal
factor
consid
vital
mechan
balanc
system
regul
potenti
therapeut
target
mani
work
identifi
dub
substrat
dub
involv
signal
shown
relev
sever
dub
tumor
progress
describ
previou
section
suppress
classic
exampl
tumorsuppress
dub
cylindromatosi
cyld
fi
rst
identifi
cation
cyld
tumor
suppressor
mutat
certain
type
cancer
includ
famili
cylindromatosi
fc
multipl
familiar
trichoepithelioma
mft
found
number
studi
underlin
molecular
mechan
cyldmedi
tumorsuppress
function
delin
import
pivot
role
cyld
regul
signal
pathway
addit
variou
studi
use
yeast
twohybrid
coimmunoprecipit
rnaibas
screen
perform
identifi
cyldregul
substrat
signal
compon
result
confi
rmed
deubiquitin
activ
cyld
regul
sever
factor
signal
pathway
essenti
modul
nemo
result
neg
regul
signal
tumorsuppress
function
contrast
defi
cienci
cyld
lead
increas
ubiquitin
target
protein
studi
use
cyld
knockout
mice
also
support
critic
function
cyld
tumor
suppress
show
enhanc
suscept
tumor
develop
inde
recent
studi
involv
clinic
patient
reveal
downregul
cyld
correl
human
colon
hepatocellular
carcinoma
chronic
lymphoid
leukemia
cll
addit
cyld
anoth
dub
neg
regul
signal
divers
compon
signal
pathway
regul
deubiquitin
capac
rnai
knockout
modelbas
valid
deubiquitin
uncov
receptorinteract
serin
threonin
protein
kinas
nemo
substrat
overal
cyld
neg
regul
pathwaymedi
tumor
progress
deubiquitin
modul
upstream
signal
mediat
known
tumorsuppress
characterist
due
activ
ph
domain
leucinerich
repeat
protein
phosphatas
phlpp
phlpp
serin
threonin
protein
phosphatas
role
neg
regul
akt
mediat
cell
surviv
signal
li
et
al
show
phlpp
downregul
upp
protect
phlpp
deubiquitin
stabil
phlpp
inde
reduc
express
phlpp
often
found
colon
cancer
patient
thu
possibl
import
regul
antiprolif
role
via
stabil
phllp
inhibit
akt
colon
cancer
previou
section
categor
dub
oncogen
tumor
suppressor
depend
major
involv
cellular
function
cell
prolifer
apoptosi
accord
relev
dub
cancer
propos
select
inhibit
catalyt
activ
dub
effi
cient
anticanc
therapeut
although
mani
inhibitor
cystein
proteas
effi
caci
inhibitor
poor
due
diffi
culti
target
enzym
hardship
gener
inhibitor
specifi
c
enzym
deriv
limit
specifi
citi
metabol
instabl
case
usp
famili
small
number
inhibitor
report
date
howev
much
effort
overcom
diffi
culti
sever
biolog
assay
use
highthroughput
screen
technolog
fl
uoresc
polar
assay
led
develop
small
inhibitor
specifi
c
dub
numer
endeavor
provid
possibl
use
dub
therapeut
target
consid
one
lead
therapeut
approach
deal
sever
diseas
includ
cancer
describ
specifi
c
dub
inhibitor
gener
andor
test
effect
drug
cancer
neural
disord
bortezomib
velcad
well
known
success
anticanc
drug
inhibit
proteasom
fda
approv
use
bortezomib
treatment
multipl
myeloma
mcl
patient
show
remark
therapeut
effi
caci
consequ
proteasom
blockad
increas
apoptosi
reduc
cancer
cell
surviv
toward
goal
develop
proteasometarget
anticanc
drug
appli
subsequ
preclin
clinic
studi
fig
proteasom
proteasom
huge
complex
kda
mass
structur
consist
two
differ
larg
subunit
center
structur
hollow
core
particl
end
core
subunit
cover
regulatori
subunit
exist
cap
like
shape
regulatori
subunit
ubiquitinbind
site
atpas
activ
site
allow
entri
substrat
catalyt
core
core
particl
provid
chamber
protein
degrad
numer
biochem
studi
perform
newli
develop
proteasom
inhibitor
test
proteasom
compos
catalyt
core
particl
form
pore
insid
two
regulatori
cap
subunit
locat
end
core
particl
fig
subunit
recogn
ubiquitin
target
protein
destin
proteasom
degrad
atpas
activ
site
ubiquitinbind
site
next
step
deubiquitin
target
transfer
catalyt
core
particl
degrad
besid
direct
blockad
proteasom
function
also
effort
target
compon
proteasom
therebi
prevent
transfer
degrad
process
one
exampl
effort
small
molecul
select
block
dub
compon
subunit
proteasom
detach
ubiquitin
molecul
ubiquitin
protein
target
proteasom
current
use
preclin
trial
effect
inhibit
proteasom
activ
give
hope
strong
proteasom
inhibitori
anticanc
drug
newli
develop
inhibitor
lee
colleagu
show
specifi
calli
inhibit
activ
proteasom
therebi
enhanc
proteasom
degrad
substrat
anoth
dub
associ
proteasom
local
lid
region
regulatori
subunit
sever
studi
reveal
pivot
cell
surviv
certain
cancer
addit
affect
drug
resist
anticanc
drug
clinic
use
debat
whether
block
also
inhibit
although
effect
uncertain
inhibitor
target
also
expect
suitabl
anticanc
drug
certain
type
cancer
one
import
protein
cancer
develop
tumor
suppressor
thu
often
call
guardian
gene
cancer
deriv
mutat
alter
function
addit
modul
function
express
level
also
affect
cellular
viabil
cancer
progress
protein
level
regul
ubiquitin
system
mediat
divers
enzym
includ
ligas
dub
ligas
target
normal
state
ubiquitin
lead
proteasom
degrad
howev
upon
dna
damag
undergo
proteasom
degrad
subsequ
prevent
degrad
key
regul
protein
deubiquitin
stabil
depend
cellular
stress
accordingli
target
protein
includ
attract
cancer
therapi
addit
develop
numer
inhibitor
interact
lead
studi
develop
inhibitor
target
recent
conduct
hbx
analogu
hbx
other
found
inhibitor
show
effect
anticanc
effect
hbx
abil
coval
bind
therebi
block
activ
lead
possibl
activ
apoptosi
cancer
cell
great
effect
reduc
multipl
myeloma
growth
overcom
bortezomib
resist
combin
drug
dexamethason
lenalidomid
andor
suberoylanilid
hydroxam
acid
saha
howev
treatment
current
preclin
stage
clinic
trial
requir
confi
rm
effi
caci
cancer
patient
wellknown
dub
due
associ
parkinson
diseas
ligas
enzym
activ
link
occur
parkinson
diseas
dimer
dimer
abil
ligat
ubiquitin
molecul
addit
shown
differ
express
pattern
certain
cancer
includ
lung
cancer
base
recent
studi
whether
sever
lung
cancer
lung
cancer
cell
line
express
normal
lung
tissu
continu
effort
develop
c
inhibitor
use
highthroughput
screen
made
isatin
oacyl
oxim
effi
cientli
inhibit
tumor
growth
lung
cancer
cell
import
enzymat
activ
regard
associ
diseas
also
brought
develop
specifi
c
inhibitor
instanc
hthieno
deriv
compound
discov
silico
drug
screen
test
inhibitori
effect
inhibitor
show
potenti
therapeut
activ
target
neural
disord
cancer
hbx
anoth
dubspecifi
c
inhibitor
block
activ
smallmolecul
inhibitor
target
prevent
cell
growth
sever
cancer
cell
line
includ
colon
cancer
cell
prostat
cancer
cell
one
wellcharacter
dub
play
import
role
dna
repair
process
combin
factor
deubiquitin
pcna
dna
repair
process
interstrand
crosslink
icl
repair
homolog
recombin
hr
repair
transles
dna
synthesi
tl
importantli
express
deregul
certain
type
cancer
suggest
may
attract
target
cancer
therapi
inde
treatment
pimozid
c
inhibitor
show
synergist
effect
nonsmal
cell
lung
cancer
nsclc
treat
anticanc
drug
cisplatin
import
uniqu
featur
dub
mention
catalyt
activ
wherebi
specifi
calli
recogn
target
ubiquitin
substrat
therefor
mani
case
dub
share
similar
domain
abil
brought
two
advanc
develop
inhibitor
dub
gener
thought
diffi
cult
gener
inhibitor
target
hot
spot
specifi
c
dub
wherea
use
gener
inhibitor
block
multipl
dub
time
inde
addit
specifi
c
dub
inhibitor
describ
sect
sever
inhibitor
could
target
two
dub
exampl
inhibitor
introduc
section
degrasyn
origin
use
inhibit
janusactiv
therebi
block
jakstat
pathway
small
molecul
also
known
inhibitori
effect
toward
bcrabl
fusion
protein
major
caus
sever
type
leukemia
howev
mani
recent
studi
demonstr
treatment
induc
polyubiquitin
protein
follow
inhibit
sever
dub
includ
effect
investig
demonstr
induc
apoptosi
affect
antiand
proapoptot
factor
includ
addit
effect
therapeut
drug
support
studi
bartholomeusz
et
al
show
treatment
combin
bortezomib
synergist
effect
anticanc
therapi
concomit
inhibit
tumor
cell
growth
modul
apoptosi
prolong
surviv
period
anim
wellknown
small
molecul
inhibit
broad
rang
dub
cystein
proteas
activitybas
chemic
proteom
reveal
treatment
result
accumul
ubiquitin
protein
suggest
anticanc
chemotherapeut
agent
chalconebas
deriv
origin
known
inhibitori
effect
proteasom
howev
investig
chalcon
deriv
show
act
inhibitor
dub
molecul
induc
remark
accumul
polyubiquitin
protein
lead
alter
express
level
cell
cycl
regul
protein
cell
cycl
arrest
tumor
cell
death
via
apoptosi
particular
abl
block
known
import
function
cell
surviv
prolifer
experiment
result
provid
rational
support
possibl
chalcon
deriv
anticanc
drug
hbx
origin
identifi
ed
c
inhibitor
colland
et
al
show
hbx
great
effect
block
enzym
activ
inact
caus
stabil
increas
apoptosi
cancer
cell
howev
recent
found
hbx
inhibitori
effect
also
dub
cyclopentenon
prostaglandin
cypg
type
prostaglandin
pg
biolog
metabolit
found
anim
bodi
certain
cypg
thought
increas
apoptosi
ubiquitin
protein
exampl
pgd
seri
pg
modifi
ed
take
biolog
activ
form
specifi
calli
cypg
j
seri
pgj
pgj
pgj
abil
coval
modifi
subsequ
inhibit
hydrolas
activ
treatment
pgj
cell
also
inhibit
without
alter
proteasom
activ
indic
prostaglandin
suitabl
neural
disord
therapi
although
dub
inhibitor
result
discuss
rais
line
evid
possibl
import
potenti
anticanc
agent
inde
block
dub
involv
abnorm
regul
caus
cancer
develop
one
emerg
anticanc
therapeut
strategi
moreov
inhibit
dub
limit
treat
cancer
shown
case
target
also
class
dub
inhibitor
papainlik
proteas
plpro
coronaviru
viral
deubiquitin
enzym
pivot
role
evad
immun
system
human
host
cell
induc
sever
acut
respiratori
syndrom
sarscov
also
abil
cleav
viral
polyprotein
function
deriv
thu
target
plpro
consid
primari
target
antivir
drug
ratia
et
al
investig
effi
cient
inhibitor
specifi
c
plpro
screen
around
librari
compound
among
show
effect
inhibit
plpro
replic
viru
without
cytotox
importantli
uncov
bind
structur
plpro
dock
catalyt
activ
site
plpro
studi
suggest
develop
promis
antivir
drug
specifi
citi
target
viral
dub
host
dub
function
turnov
protein
pivot
regul
mechan
cellular
process
follow
posttransl
modifi
cation
protein
phosphoryl
methyl
ubiquitin
particular
cellular
homeostasi
protein
need
degrad
newli
synthes
protein
undergo
two
differ
degrad
pathway
either
lysosom
proteasom
cellular
protein
tag
ubiquitin
follow
proteasom
degrad
wellorgan
upp
sever
hundr
ligas
help
protein
conjug
ubiquitin
wherea
far
fewer
number
dub
respons
revers
remov
ubiquitin
ubiquitin
protein
regard
dub
numer
substrat
deregul
certain
dub
alter
cellular
process
via
substraterel
function
indic
dub
import
regul
cell
describ
relev
dub
cancer
caus
deregul
dub
express
alter
enzymat
activ
complex
effect
substrat
function
mani
case
dub
inhibitor
shown
anticanc
effect
mainli
preclin
level
applic
anticanc
drug
valid
clinic
set
bortezomib
use
anticanc
drug
problem
associ
use
includ
bortezomib
resist
sever
toxic
lower
therapeut
effect
individu
solid
tumor
thu
treatment
involv
combin
agent
recommend
current
cancer
therapi
result
need
effect
drug
target
cancer
also
diseas
numer
studi
hypothes
valid
far
dub
may
one
ideal
attract
target
